Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorYiğit, Kenan
dc.contributor.authorİnan, Ümit Ubeyt
dc.contributor.authorİnan, Sibel
dc.contributor.authorDoğan, Mustafa
dc.contributor.authorYavaş, Güliz Fatma
dc.contributor.authorÇetinkaya, Ersan
dc.date.accessioned2021-05-05T22:14:04Z
dc.date.available2021-05-05T22:14:04Z
dc.date.issued2021
dc.identifier.issn0165-5701
dc.identifier.issn1573-2630
dc.identifier.urihttps://doi.org/10.1007/s10792-021-01712-5
dc.identifier.urihttps://hdl.handle.net/20.500.12933/249
dc.descriptionWOS:000611076300002en_US
dc.descriptionPubMed: 33486648en_US
dc.description.abstractPurpose To investigate changes in macular and panretinal neuroretinal functions by electroretinographic examinations in eyes with diabetic macular edema (DME) treated with intravitreal ranibizumab. Material and methods Sixty-four patients with DME were included in this prospective study. Patients were treated with ranibizumab injection according to the PRN regimen for over 12 months. Before treatment, all patients underwent fundus fluorescein angiography, optical coherence tomography (OCT), best-corrected visual acuity (BCVA) assessment, full-field (ff-ERG), and multifocal electroretinography (mf-ERG). In monthly visits, BCVA and OCT were performed. Besides, mf-ERG recordings were obtained at months 3, 6, 9, and 12, and ff-ERG was performed at month 12. Results Fifty-eight patients completed the study. The mean age was 61.1 +/- 8.5 (39-80) years. The mean number of injections was 6.19 +/- 1.9. The decimal BCVA improved from 0.30 to 0.45 during the 12-month follow-up (p < 0.05). Macular thickness decreased from 413.5 mu m to 329.5 mu m (p < 0.05). The mf-ERG recordings in the central macular region showed improvements N1 and P1 amplitudes at months 9 and 12. There was a positive correlation between the baseline central (p < 001; r: - 0.378 and p < 0.05; r:-0.335, respectively), the second ring (p < 0.05; r: - 0.260 and p < 0.05; r: - 0.270, respectively) P1- and N1-wave amplitudes, and the BCVA at month 12. Full-field ERG recordings showed that peripheral neuroretinal responses were maintained or improved at month 12. Statistically significant improvements in BCVA and macular thickness were observed at all follow-up visits. Conclusion Multifocal electroretinographic recording started to improve 6 months after the beginning of intravitreal ranibizumab treatment in eyes with DME. This improvement was significant at months 9 and 12. A significant improvement in ff-ERG was observed at month 12.en_US
dc.description.sponsorshipKocatepe University Scientific Research CommitteeAfyon Kocatepe University; Department of Ophthalmology in the Kocatepe University [14.TUS.02]en_US
dc.description.sponsorshipKocatepe University Scientific Research Committee provided financial support in the form of technical equipment for use in this Project and Department of Ophthalmology in the Kocatepe University (Project Number: 14.TUS.02). The sponsor had no role in the design or conduct of this research.en_US
dc.language.isoengen_US
dc.publisherSpringeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetic macular edemaen_US
dc.subjectElectroretinographyen_US
dc.subjectNeuroretinal functionsen_US
dc.subjectRanibizumaben_US
dc.titleLong-term full-field and multifocal electroretinographic changes after treatment with ranibizumab in patients with diabetic macular edemaen_US
dc.typearticleen_US
dc.departmentAFSÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Göz Hastalıkları Ana Bilim Dalıen_US
dc.contributor.institutionauthorİnan, Sibel
dc.contributor.institutionauthorDoğan, Mustafa
dc.identifier.doi10.1007/s10792-021-01712-5
dc.identifier.volume41en_US
dc.identifier.issue4en_US
dc.identifier.startpage1487en_US
dc.identifier.endpage1501en_US
dc.relation.journalInternational Ophthalmologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster